21JUL

WHO issues its first fungal blueprint

2 min read

09:12UTC

The World Health Organization published its first blueprint on fungal disease on 1 July, estimating more than 300 million people suffer serious fungal illness each year.

← Back to Ebola outruns its own contact tracing Jump to analysis ↓

ScienceAssessed

Key takeaway

WHO's first fungal blueprint names a 300-million-case burden that global resistance strategy had tracked only in bacteria.

The World Health Organization (WHO) published its first dedicated Blueprint on fungal disease and antifungal resistance on Wednesday 1 July, estimating that more than 300 million people suffer serious fungal disease each year ¹. The report says plainly that fungal disease is "largely absent from national health plans, global burden-of-disease estimates" and from mainstream antimicrobial resistance (AMR) strategy.

The blueprint sets four action domains and 12 national entry points, building on WHO's existing fungal priority pathogens list, which includes Candida auris, a drug-resistant yeast that spreads in hospitals and shrugs off first-line antifungals. Antimicrobial resistance is the broader field of pathogens surviving the drugs meant to kill them, and until now its surveillance counted only bacteria.

WHO's GLASS surveillance found in 2025 that one in six bacterial infections is now resistant , and the ten-year GAP-AMR plan adopted in May set targets for bacterial deaths alone . Fungi sat outside both. The blueprint is WHO's first attempt to name that omission and hand countries a governance scaffold for closing it.

Deep Analysis

In plain English

Antimicrobial resistance is when infections stop responding to the drugs normally used to treat them. Until now, global tracking of this problem has focused almost entirely on bacteria, even though fungal infections can be just as resistant and just as deadly. On 1 July, the World Health Organization published its first-ever policy document dedicated to fungal disease and antifungal resistance, estimating that more than 300 million people suffer a serious fungal infection every year. Candida auris, a drug-resistant yeast that spreads in hospitals, is one of the pathogens named in the Blueprint.

What could happen next?

Meaning
Fungal disease's inclusion in a WHO framework does not itself fund the laboratory capacity needed to track it in the countries carrying the highest burden.

Source Landscape

This story draws on neutral-leaning sources from Switzerland

Switzerland

Primary parallel: WHO's 2017 bacterial priority pathogens list named the resistance threat years before dedicated antifungal or antibacterial R&D funding followed, the same list-first, funding-later sequence this fungal Blueprint now begins.

Counter-parallel: The 2022 mpox PHEIC drew emergency funding and vaccine allocation within months of declaration, because an active outbreak with rising case counts creates faster political urgency than a standing disease-burden estimate does, a contrast suggesting this Blueprint may move at the bacterial list's slower pace rather than an outbreak's faster one.

Consensus view: The WHO Blueprint frames fungal disease as invisible by policy design, not by epidemiology, since the decade-long Global Action Plan on Antimicrobial Resistance adopted in May 2026 and the GLASS surveillance system both track bacterial resistance only, leaving an estimated 300 million annual serious fungal cases outside any global reporting mechanism.

Counter-view: Africa CDC's ARILAC laboratory-capacity programme, which found only 1.3% of assessed African laboratories conduct routine AMR testing of any kind, suggests the Blueprint's surveillance ambitions are unreachable in the same countries carrying the heaviest fungal burden until basic lab infrastructure is funded first.

Key tension: Whether naming fungal disease in a global framework accelerates funding toward the labs that need it, or simply adds an unfunded reporting requirement to systems already failing on bacterial surveillance.

Sources:WHO

Mentions:World Health Organization →WHO Blueprint on fungal disease and antifungal resistance →Candida auris →ARILAC →Africa CDC →PHEIC →

First Reported In

Update #10 · Ebola's responders are now the casualties

WHO· 14 Jul 2026

Read original →

Causes and effects

Caused by

One in six infections beats the drug

WHO GLASS's bacterial-only resistance findings left fungal disease outside AMR surveillance until this Blueprint.

Occurred 1 Jun 2026

Read story →

WHA79 adopts a 10-year AMR plan

The ten-year GAP-AMR plan adopted in May addressed bacterial resistance only, a gap the fungal Blueprint now names explicitly.

Occurred 23 May 2026

Read story →

This Event

WHO issues its first fungal blueprint

WHO's blueprint pulls fungal disease into a resistance strategy that until now tracked only bacteria.

Different Perspectives

UK Government

The Biological Security Strategy implementation report published 14 July commits the UK to deciding within twelve months whether to make DNA-synthesis screening mandatory, backed by GBP 1.83bn for biosecurity centres. It is a preemptive move on a threat that has not yet produced a UK incident.

Cambodia's Ministry of Health

Cambodia confirmed a nine-month-old girl in Phnom Penh as its fourth 2026 H5N1 case on 11 July, the country supplying four of the world's seven new human cases since February. The ministry's confirmed-case cadence is running well ahead of a US surveillance system that has recorded nothing new since March.

Knowledge Ecology International

KEI published proposed annex text on the day IGWG7 opened that would attach benefit-sharing duties to a product's market registration, regardless of whether the manufacturer used shared samples or only downloaded sequence data. It is the Africa Group's fallback position if the sample-based bargain fails to bind.

European Union

The EU and other industrialised states backed a hybrid model built on centralised infrastructure with more flexible access terms, the opposite design choice from the Africa Group's. Brussels wants conditions handled contractually once samples reach shared facilities, not attached to national custody of the material itself.

Africa Group / Algeria

Algeria, speaking for the Africa Group at IGWG7, backed distributed national and regional laboratories under binding access conditions, arguing that supplying states must keep legal control of samples rather than surrender them into shared infrastructure.

Uganda's Ministry of Health

Uganda discharged its last confirmed patient on 16 July and opened a 42-day countdown to declaring its own outbreak over, closing at 20 cases and 2 deaths with no new case since 21 June. This is a closing chapter running alongside DR Congo's still-worsening one, contingent on a border DRC can no longer see across.